{"answer":{"query":"Rhopressa","resolved_as":"applications","packages":2,"applications":["NDA208254"],"identity":{"application_numbers":["NDA208254"],"marketing_categories":["NDA"],"labelers":[],"dosage_forms":[{"text":"SOLUTION/ DROPS","untrusted":true}],"marketing_start":{"earliest":"2017-12-18","latest":"2017-12-18","packages_with_a_start_date":2}},"generic_entry":[{"application":"NDA208254","date":"2034-03-14","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10588901","productNo":"001"},"latest_patent_expiry":"2034-03-14","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":15,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":15,"exclusivities_listed":0,"fact_id":"96eeb2a40326c4edc71badc0"}],"label_history":{"events_total":2,"non_cmc_events":2,"counts_by_class":{"LABELING":2},"cmc_events":0,"recent_non_cmc_events":[{"application":"NDA208254","submission_no":14,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-09-18","documents":[{"type":"Letter","date":"2024-09-19","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208254Orig1s014ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-09-20","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208254s014lbl.pdf","untrusted":true}}],"fact_id":"9b898eeaab26ba80e42dab77"},{"application":"NDA208254","submission_no":3,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2019-03-22","documents":[{"type":"Label","date":"2019-03-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208254s003lbl.pdf","untrusted":true}}],"fact_id":"d95923e1fce909556ae851df"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA208254","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"RHOPRESSA","untrusted":true},"form":{"text":"SOLUTION/DROPS;OPHTHALMIC","untrusted":true},"strength":{"text":"EQ 0.02% BASE","untrusted":true}}]},"spending":{"reported_under":{"generic":{"text":"Netarsudil Mesylate","untrusted":true},"brand":{"text":"Rhopressa","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":109355175.17,"claims":279360,"beneficiaries":68841,"average_spending_per_claim_usd":391.44893746,"fact_id":"32c66df254a8663b1a3ddfb0"},{"year":2021,"gross_spending_usd":134396762.4,"claims":312200,"beneficiaries":81454,"average_spending_per_claim_usd":430.48290327,"fact_id":"f4b9e19aa787bd1d2c6d51bd"},{"year":2022,"gross_spending_usd":160954923.91,"claims":343905,"beneficiaries":87838,"average_spending_per_claim_usd":468.02147078,"fact_id":"7d0ae826f653895f44516828"},{"year":2023,"gross_spending_usd":174888744.43,"claims":347603,"beneficiaries":89044,"average_spending_per_claim_usd":503.12783385,"fact_id":"51c7ea4deb345839b661808a"},{"year":2024,"gross_spending_usd":168045637.46,"claims":353836,"beneficiaries":89311,"average_spending_per_claim_usd":474.92521241,"fact_id":"e27eea89c2b2b9d7a3984fe9"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":1,"all_states_medicaid_reimbursed_usd":83544.34,"all_states_medicaid_paid_prescriptions":227,"top_states":[{"state":"MN","medicaid_paid_prescriptions":227,"medicaid_reimbursed_usd":83544.34,"total_reimbursed_usd":83544.34,"packages":1,"covers":"fee_for_service_only","fact_id":"0b88b7c1e2aa449ec04a7a0f"}],"unlabelled_state_code_xx":null,"built_from_facts":1,"facts_fee_for_service_only":1,"older_year_facts_not_used":40,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"b57f9f454ed3f15f1aba0902","field":"ndc.listing","entity":"ndc:70727049725"},{"fact_id":"a9b5b70668271d63cc131021","field":"ndc.listing","entity":"ndc:70727049799"},{"fact_id":"96eeb2a40326c4edc71badc0","field":"drug.generic_entry_earliest","entity":"application:NDA208254"},{"fact_id":"abfcf3986e1509aeca3e06c3","field":"drug.patent","entity":"application:NDA208254"},{"fact_id":"9b898eeaab26ba80e42dab77","field":"drug.label_event","entity":"application:NDA208254"},{"fact_id":"d95923e1fce909556ae851df","field":"drug.label_event","entity":"application:NDA208254"},{"fact_id":"3da888494afe094348932a85","field":"drug.marketing_status","entity":"application:NDA208254"},{"fact_id":"32c66df254a8663b1a3ddfb0","field":"drug.partd_spending","entity":"drug:netarsudil-mesylate|rhopressa"},{"fact_id":"f4b9e19aa787bd1d2c6d51bd","field":"drug.partd_spending","entity":"drug:netarsudil-mesylate|rhopressa"},{"fact_id":"7d0ae826f653895f44516828","field":"drug.partd_spending","entity":"drug:netarsudil-mesylate|rhopressa"},{"fact_id":"51c7ea4deb345839b661808a","field":"drug.partd_spending","entity":"drug:netarsudil-mesylate|rhopressa"},{"fact_id":"e27eea89c2b2b9d7a3984fe9","field":"drug.partd_spending","entity":"drug:netarsudil-mesylate|rhopressa"},{"fact_id":"0b88b7c1e2aa449ec04a7a0f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:70727049725:MN"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"trials","reason":"no ClinicalTrials.gov record set for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}